August 15, 2017 6:04pm

 

Forget the “Blues Brothers”

… When I get the volatility virus, I flop open the “barf” bag

… When I get totally fed up with momentum condition, I flip the trade

 

Pre-open indications: 3 hit and 3 miss

Follow-up, Biostage dropped another -$0.065 after yesterday’s -$0.09 as an S-1 for stock right’s holders – what a “sham”! Investors no longer have any rights under this financing especially since its BOD has or will NOT make ANY recommendation. The reason for this S-1 filing, to keep management paid in a failed company that continues to misconstrue any truth to its real status! Look for the stock to be under $0.30.

Shame on this CEO and BOD, they OWN this downward spiral and its collateral shareholder damage …!

I say, clean-out this shareholder temple of these scoundrels and reprobates!

 

It’s called premium content for a reason … I define insight  from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!

Others don’t even come close!

 

I answer one question, in which company should investors commit and keep their money.

 

Tuesday’s results have implications to Wednesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

Henry’omics:

From the pre-open’s investor’s newsletter, “… momentum or volatility - which one do you want to depend on or lose to? Was it a relief rally on Monday and will it continue – it didn’t. They why I added … “I live by the fifteen (15%) percent rule, up and out, down and in!”

 

Just when I had hope for the sector, the charlatans take-over … as Biostage (BSTG)  shows its TRUE colors re shareholders … scammers!

Risk factors …

  • Is a terminal death suit against Biostage (BSTG)  a risk factor ?

 

Referencing the title: Biostage’s newest S-1 filing …

http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11754557&type=HTML&symbol=BSTG&companyName=Biostage+Inc.&formType=S-1&dateFiled=2017-08-15&cik=0001563665

 

Where did the CEO in his new filing, hide the staus of the terminal death suit …

 

How many down financings does it take for investors to say … I HAVE HAD ENOUGH?

Yet, they haven’t forgotten to indemnify themselves from any shareholder blow-back …

  • We agreed to indemnify the backstop provider and its affiliates and each of their respective officers, directors, partners, employees, agents and representatives for losses arising out of this offering and the related registration statement and prospectus (other than with respect to statements made in reliance on information provided to us in writing by the backstop provider for use herein) and claims, suits or proceedings challenging the authorization, execution, delivery, performance or termination of a rights offering, the Backstop Agreement and certain ancillary agreements and/or any of the transactions contemplated thereby, other than losses arising out of or related to any breach by the backstop provider of the Backstop Agreement.
  • The backstop providers agreed to indemnify us and our affiliates and each of our respective officers, directors, partners, employees, agents and representatives for losses arising out of or relating to statements or omissions in the registration statement or prospectus for this offering (or any amendment or supplement thereto) made in reliance on or in conformity with written information relating to the backstop provider furnished to us by or on behalf of the backstop provider expressly for use therein.

 

As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our Amended and Restated Certificate of Incorporation, or our Charter, and Second Amended and Restated Bylaws, or our Bylaws, that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

  • any breach of the director’s duty of loyalty to us or our stockholders;
  • any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
  • any transaction from which the director derived an improper personal benefit.

How is “ANY” defined by this CEO and his foreknowledge of other individuals?

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

  • The first hour was negative with an A/DL of 10/30 and 3 flats;
  • The mid-day was negative with an A/DL of 15/24 and 4 flat;
  • The close was negative  with an A/DL of 15/24 and 4 flat;

 

Pre-open indications:  3 hit and 3 miss

  • Asterias Biotherapeutics (NYSEMKT: AST) closed down -$0.20 – hit;
  • Biostage (BSTG) closed down -$0.065 – hit;
  • BioLife Solutions (BLFS) closed up + $0.16 – miss;
  • Fate Therapeutics (FATE) closed up +$0.09 – hit;
  • Kite Pharma (KITE) closed up +$3.94 – miss;
  • Sangamo Therapeutics (SGMO) closed down -$0.40 – miss;

 

Regenerative Medicine Earnings Scorecard - Q2/2017 - to date … 30 out of 43 covered – so far

http://www.regmedinvestors.com/articles/9841

 

Daily analytics:

The Dow managed to eke out a third day of gains, but overall the main benchmarks ended little changed amid better-then-expected retail sales data and an abatement of tensions between the U.S. and North Korea.

  • The Dow finished up 5.28 points, or less than 0.1%, at 21,998.99. The S&P 500 index declined 1.23 points to finish at 2,464.61. The NASDAQ slipped 7.22 points, or 0.1%, to close at 6,333.01.
  • All three indexes had traded higher earlier in the session, and at its peak of the day, the S&P moved within 1% point of record levels.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Tuesday traded at 12.04, down -2.35% …

  • Monday traded at 12.38 and was down -20.18% …Friday traded at 15.51, down -3.20% following Thursday’s 16.04, a +44.37% increase, Wednesday traded at 11.19, up +2.10% and last Tuesday traded at 11.03, up +11.08%

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

  • Tuesday was down -0.81%
  • Monday +1.49%
  • Friday +0.15%
  • Thursday -1.82%
  • Wednesday -0.86%
  • Last Tuesday  -0.31%

 

… The iShares NASDAQ Biotechnology (IBB) indicated:

  • Tuesday was up +0.09%
  • Monday +1.03%
  • Friday +0.64%
  • Thursday -2.82%
  • Wednesday -0.32%
  • Last Tuesday -9,94%

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %’s migrate…

  • Tuesday’s decliners ranged from -0.38% <FCSC> to -15.29% <BSTG> in 24 equities;
  • Monday’s decliners ranged from -0.24% <RGNX> to -17.71% <BSTG> in 12 equities;
  • Friday’s decliners ranged from -0.46% <KITE> to -11.97% <IMUC> in 14 equities;
  • Thursday’s decliners ranged from -0.31% <KITE> to -11.52% <VSTM> in 33 equities;
  • Wednesday’s decliners ranged from -0.16% <OSIR> to -21.24% <BLCM> in 31 equities;
  • Last Tuesday’s decliners ranged from -0.46% <BCLI> to -11.11% <CUR> in 28 equities;

 

Versus

… Look at the percentage’s (%) and spreads …

  • Tuesday’s gainers ranged from +0.43% <XON> to +6.08% <MDXG> in 15 equities;
  • Monday’s gainers ranged from +0.88% <ADRO> to +26% <IMUC> in 28 equities;
  • Friday’s gainers ranged from +0.06% <BSTG> to +11.43% <CUR> in 28 equities;
  • Thursday’s gainers ranged from +0.32% <OSIR> to +12.43% <SGMO> in 8 equities;
  • Wednesday’s gainers ranged from +0.71% <KITE> to +13.33% <VCEL> in 10 equities;
  • Last Monday’s gainers ranged from +0.12%  <IMUC> to +30.43% <BSTG> in 22 equities;

 

Some of MY working trend lines or indications:

  • The greatest volume to the downside:  BSTG, SGMO, IMUC and CYTX
  • Upside volume was weighted to:  MDXG, XON, KITE, JUNO and ATHX
  • Biggest $ downside:  ONCE, SGMO, AXGN, AST and AGTC
  • Largest $ upside:  KITE, MDXG, RGBX, BLUE, CLLS and STML
  • Flat: VCEL, ADVM, RENE.L and PSTI

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.